Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia
Journal article
Nicholas R Livingston, Peter CT Hawkins, James Gilleen, Rong Ye, Lorena Valdearenas, Sukhi Shergill and Mitul A Mehta 2021. Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia. Journal of Psychopharmacology. 35 (9). https://doi.org/10.1177/02698811211000778
Authors | Nicholas R Livingston, Peter CT Hawkins, James Gilleen, Rong Ye, Lorena Valdearenas, Sukhi Shergill and Mitul A Mehta |
---|---|
Abstract | Background: Aims: Methods: Results: Conclusions: |
Keywords | Schizophrenia; Phosphodiesterase inhibitor; Cognitive defect; Attentional set-shifting; Functional magnetic resonance imaging |
Year | 2021 |
Journal | Journal of Psychopharmacology |
Journal citation | 35 (9) |
Publisher | SAGE |
ISSN | 0269-8811 |
1461-7285 | |
Digital Object Identifier (DOI) | https://doi.org/10.1177/02698811211000778 |
Official URL | https://journals.sagepub.com/doi/full/10.1177/02698811211000778 |
Publication dates | |
Online | 28 Apr 2021 |
Publication process dates | |
Deposited | 02 Jun 2023 |
Publisher's version | License |
Output status | Published |
https://repository.canterbury.ac.uk/item/94vwq/preliminary-evidence-for-the-phosphodiesterase-type-4-inhibitor-roflumilast-in-ameliorating-cognitive-flexibility-deficits-in-patients-with-schizophrenia
Download files
Publisher's version
28
total views13
total downloads0
views this month3
downloads this month